Comparing Semaglutide with the most widely used GLP-1 receptor therapies
View Full ComparisonGLP-1 medications share a common mechanism of appetite regulation and glucose control, but differ in molecular structure, dosing frequency, and clinical outcomes.
Semaglutide remains a reference standard in GLP-1 therapy for both weight loss and type 2 diabetes management.
Explore Semaglutide Guide| Medication | Semaglutide ⭐ Core Focus | Other GLP-1 Agonists |
|---|---|---|
| Examples | Ozempic, Wegovy, Rybelsus | Liraglutide, Dulaglutide, Exenatide |
| Weight Loss | 10–15% | 5–10% (varies by drug) |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonists (older generation) |
| Dosing Frequency | Weekly | Daily or weekly (depends on drug) |
| Appetite Suppression | Strong | Moderate to strong |
| Clinical Evidence | Extensive modern trials | Established but older datasets |
| Overall Efficacy | High | Moderate to high |
Among GLP-1 receptor agonists, Semaglutide is currently one of the most effective and widely validated options, particularly for weight loss and metabolic improvement.
Other GLP-1 medications remain clinically useful, but generally demonstrate lower average weight reduction and require more frequent dosing.
View Semaglutide Dosage GuideExplore dosage, cost, and clinical results in detail.
Cost & Availability Side Effects